Deramiocel Review Extended
FDA Extends Capricor's Deramiocel Review to November Following Data Amendment
Key Points
The FDA classified Capricor's BLA amendment for Deramiocel as a major amendment, extending the PDUFA review by three months to November 22, 2026.
Deramiocel (CAP-1002) is an allogeneic cardiosphere-derived cell therapy designed to preserve skeletal and cardiac muscle function through immunomodulatory and anti-fibrotic effects.
Deramiocel carries multiple regulatory designations in the U.S. and Europe, including Orphan Drug, RMAT and Rare Pediatric Disease in the U.S., plus Orphan Drug and ATMP designations in Europe.
The amendment includes 24-month open-label HOPE-3 data and robustness analyses intended to support a refined indication focused on upper limb function.
CEO Linda Marbán said the extended follow-up yields one of the most extensive clinical datasets evaluating upper limb function in Duchenne.
The FDA has extended its review of Capricor Therapeutics' Deramiocel cell therapy by three months, pushing the decision date to November 22, 2026 from August 22, 2026. Reuters reported that the extension came after Capricor submitted a major amendment with 24 months of open-label data from the HOPE-3 trial, focusing on how well the therapy preserves upper limb function in Duchenne muscular dystrophy patients.
The FDA classified Capricor's submission as a major amendment, which triggers a longer review process. GuruFocus noted that Deramiocel is an allogeneic cell therapy designed to slow muscle damage through anti-inflammatory and anti-fibrotic effects. The company has secured multiple regulatory designations including Orphan Drug status and Rare Pediatric Disease designation in the U.S.
What Deramiocel Does and Why It Matters
Deramiocel, also called CAP-1002, is made from cardiosphere-derived cells taken from a donor heart. GuruFocus explained that the therapy works by reducing inflammation and fibrosis in muscle tissue. For Duchenne muscular dystrophy, a devastating genetic disease that weakens muscles progressively, preserving upper limb function is critical—it helps patients maintain independence and quality of life.
Duchenne affects roughly 1 in 3,500 boys worldwide. Current treatments slow decline but do not stop it. The new clinical dataset from HOPE-3 represents one of the most extensive studies of upper limb preservation in Duchenne, according to CEO Linda Marbán. This data forms the backbone of Capricor's refined indication strategy.
Why the FDA Requested More Time
Major amendments to a biologics license application trigger additional FDA review time. TipRanks noted that Capricor's submission included new analyses and extended follow-up data that required the regulator to perform deeper evaluation. The three-month extension is standard when sponsors add substantial new clinical evidence mid-review.
The July 2026 FDA advisory committee meeting also influenced the agency's decision to request more information. This type of extension typically signals the FDA wants to fully assess the new data before making a final determination. A November decision gives reviewers time to evaluate whether upper limb preservation alone justifies approval.
The Company's Financial Reality Versus Clinical Promise
Capricor is burning cash and has reported ongoing losses. Some analysts rate the stock as Neutral despite positive clinical progress. GuruFocus coverage highlighted that investor sentiment remains cautious—the company's financials are a concern even as the Deramiocel data improves.
The stock initially surged more than 20% on the extension announcement, Yahoo News Malaysia reported. However, long-term investor confidence depends on whether Capricor can secure FDA approval and eventually turn a profit. The November decision will be the critical test for both the therapy and the company's survival.
What Happens Next: The November 2026 Timeline
Capricor now has until November 22, 2026 to see if the FDA will approve Deramiocel for its refined upper limb indication. The company argues the extended HOPE-3 data and robustness analyses strongly support approval. European regulators have also granted Orphan Drug and Advanced Therapy Medicinal Product designations, opening another path forward.
If approved, Deramiocel would be a major breakthrough for Duchenne patients with limited treatment options. Capricor emphasizes the substantial unmet medical need and the extensive clinical evidence showing upper limb benefit. The next four months will be crucial for the company and the thousands of families waiting for new DMD therapies.
Sentiment
Mostly PositivePublishers
13
Articles
80
Reach
93
